 Vyant Bio NASDAQ:VYNT Inc ended its 2021 financial year with a beefed-up cash balance of 20.6 million to help the biotechnology company pursue its development of drugs for complex neurodevelopmental and neurodegenerative disorders. The company is focused primarily on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome, CDKL5 Deficiency Disorder, and familial Parkinsons Disease. 